You are here

Ovid Therapeutics

Ovid partners with Waksal startup to develop drugs for rare brain disorders

Ovid partners with Waksal startup to develop drugs for rare brain disorders

BioPharma Dive

Ovid Therapeutics

Graviton Biosciences

drug development

brain disorders

Flag link:

3 biotech executives on the year ahead: deals, drug pricing and the down market

3 biotech executives on the year ahead: deals, drug pricing and the down market

BioPharma Dive

Ovid Therapeutics

Flag link:

Ovid takes a novel approach to gene therapy

Ovid takes a novel approach to gene therapy

EP Vantage

Ovid Therapeutics

Flag link:

'Stay alive': Wave of layoffs crashes into biotech startup inferno

'Stay alive': Wave of layoffs crashes into biotech startup inferno

Fierce Biotech

Ovid Therapeutics

Flag link:

Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X

Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile X

Fierce Biotech

Ovid Therapeutics

Flag link:

Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline

Ovid signs license deal with AstraZeneca to expand epilepsy drug pipeline

Pharmaceutical Business Review

Ovid Therapeutics

small molecule drugs

Flag link:

Ovid shuffles C-suite, lays off staff in wake of PhIII Angelman syndrome fail

Ovid shuffles C-suite, lays off staff in wake of PhIII Angelman syndrome fail

Endpoints

Ovid Therapeutics

Angelman Syndrome

clinical trials

Flag link:

Ovid cuts its losses on controversial Angelman syndrome drug, making its crushing development halt permanent

Ovid cuts its losses on controversial Angelman syndrome drug, making its crushing development halt permanent

Endpoints

Ovid Therapeutics

Angelman Syndrome

Flag link:

Ovid crashes out in Angelman syndrome

Ovid crashes out in Angelman syndrome

EP Vantage

Ovid Therapeutics

clinical trials

Angelman Syndrome

Flag link:

Ovid shows mixed results on epilepsy program

Ovid shows mixed results on epilepsy program

Endpoints

Ovid Therapeutics

clinical trials

Flag link:

Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?

Ovid gets quick raise off PhII seizure results. Can the results hold up against GW?

Endpoints

Ovid Therapeutics

clinical trials

Dravet syndrome

Lennox-Gastaut Syndrome

Flag link:

Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma

Ovid Licenses European Rights to Lead Rare Disease Drug to Angelini Pharma

Xconomy

Ovid Therapeutics

Angelman Syndrome

Angelini Pharma

clinical trials

Flag link:

Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward

Ovid's lead drug shows promising efficacy signal in Fragile X syndrome study, but optimal dosing regimen is unclear for path forward

Endpoints

Ovid Therapeutics

Fragile X syndrome

clinical trials

Flag link:

Top Companies in Pharm Country Ranked by Revenue

Top Companies in Pharm Country Ranked by Revenue

BioSpace

Bristol-Myers Squibb

Ovid Therapeutics

Flag link:

With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite

With “Inflection Year” Ahead, Ovid Adds Novartis’s Tardio to C-Suite

Xconomy

Ovid Therapeutics

Flag link:

Positive Results For Ovid Drug, But Questions Remain

Positive Results For Ovid Drug, But Questions Remain

Forbes

Angelman Syndrome

Ovid Therapeutics

Flag link:

Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)

Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)

CP Wire

Ovid Therapeutics

Flag link:

Takeda and Ovid Therapeutics Expand Clinical Program for TAK-935/OV935 with New Studies in Rare Developmental and Epileptic Encephalopathies (DEE)

Ovid Therapeutics

developmental epileptic encephalopathies

Flag link:

Biotech, pharma chime in over Trump’s move to halt immigration program

Biotech, pharma chime in over Trump’s move to halt immigration program

Drug Delivery Business News

pharma industry

Decibel Therapeutics

Ovid Therapeutics

Flag link:

Pages